FDA, EU Investigating Probable Carcinogen in Heartburn Meds

Share this post

Drug regulators in the US and Europe find the probable carcinogen NDMA in heartburn medicines containing ranitidine, reminiscent of the ‘sartan’ contamination saga.
News Alerts

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply